Roche reports positive early results for obesity candidate

16 May 2024
roche_hq_large

Confirming progress on its $2.7 billion bet to get into the weight management sector, Swiss pharma giant Roche (ROG: SIX) today released positive results from the Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes that came with its acquisition last year of Carmot Therapeutics.

Roche’s shares gained as much as 4.7% on Thursday and were still up 3.6% at 235.60 Swiss francs by late afternoon.

Roche is one of the latest companies that are increasingly seeking to cash in on the rapidly-expanding market for obesity drugs, which has seen GLP-1 agonist Wegovy (semaglutide)-maker Novo Nordisk (NOV: N) become the most valuable company in Europe. But the Danish firm is already facing strong competition from US major Eli Lilly (NYSE: LLY), whose obesity drug Zepbound (tirzepatide) is making big waves in the sector.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical